Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- ZIM +2.7%, BNTX +2.6% (guidance)
Other news:
- NVAX +11.7% (COVID-19 vaccine gets FDA approval)
- TXNM +9.2% (announced an agreement under which Blackstone Infrastructure (BX) will acquire TXNM Energy for $61.25/share in cash upon closing)
- NTLA +5.9% (Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran)
- TECX +4.8% (Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking Presentation at ESC Heart Failure 2025)
- FIP +4.5% (files for 22,237,370 share common stock offering by selling shareholders)
- SVRA +3.3% (Presented New Data From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at American Thoracic Society Conference)
- ZLAB +2.7% (receives U.S. FDA fast track designation for ZL-1310, a DLL3-targeted antibody-drug conjugate, for treatment of extensive-stage small cell lung cancer)
- PACS +1.8% (to delay 10-Q filing)